Trials / Recruiting
RecruitingNCT06260514
Study of APR-1051 in Patients With Advanced Solid Tumors
A Phase 1, Open-Label, Multicenter, First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of APR-1051 in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Aprea Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and effectiveness of APR-1051 through the performance of a Phase 1, open-label, safety, PK, and preliminary efficacy study of oral APR-1051 in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | APR-1051 | WEE1 Inhibitor |
Timeline
- Start date
- 2024-06-13
- Primary completion
- 2027-06-01
- Completion
- 2028-06-01
- First posted
- 2024-02-15
- Last updated
- 2026-01-26
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06260514. Inclusion in this directory is not an endorsement.